Praxis Precision Medicines公司宣布,针对其在研药物Ulixacaltamide与Relutrigine的两项新药申请(NDA),预计将于2026年2月中旬前提交。其中,Ulixacaltamide的适应症为特发性震颤,而Relutrigine则旨在治疗与SCN2A及SCN8A基因相关的疾病。这一进展标志着公司在推进其精准医疗管线方面迈出了关键一步。
Praxis Precision Medicines公司宣布,针对其在研药物Ulixacaltamide与Relutrigine的两项新药申请(NDA),预计将于2026年2月中旬前提交。其中,Ulixacaltamide的适应症为特发性震颤,而Relutrigine则旨在治疗与SCN2A及SCN8A基因相关的疾病。这一进展标志着公司在推进其精准医疗管线方面迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.